Emkay Global Financial Services Limited has submitted a regulatory disclosure to the National Stock Exchange of India Limited and BSE Limited regarding the completion of term of Dr. Satish Ugrankar (DIN: 00043783) as Non-Executive - Independent Director of the Company.
The disclosure is made pursuant to Regulations 30 and 51 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations).
Dr. Satish Ugrankar completed his second term of 5 consecutive years as an Independent Director of the Company on 9th August, 2026. Consequently, he ceases to be a Member of the Board of Directors of the Company upon completion of his term.
As a result of this cessation, Dr. Ugrankar also ceases to hold the following committee positions:
- Chairperson of Stakeholder's Relationship Committee
- Member of Audit Committee
- Member of Nomination, Remuneration and Compensation Committee of the Board
The Board of Directors placed on record its deep appreciation for the valuable contributions and guidance rendered by Dr. Satish Ugrankar during his tenure as an Independent Director of the Company.
The disclosure includes Annexure A which provides the details required under Regulation 30 read with Schedule III to the SEBI Listing Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.
The intimation has been uploaded on the Company's website at www.emkayglobal.com.
No financial impact has been quantified in this disclosure. The change is administrative and governance-related in nature.